Upgrade to SI Premium - Free Trial

Seattle Genetics (SGEN) Grantred FDA Supplemental Biologics License Application and Grants Priority Review for ADCETRIS (Brentuximab Vedotin)

January 2, 2018 8:01 AM
Seattle Genetics, Inc. (NASDAQ: SGEN) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

Next Articles